TMEFF2

Aliases
  • CT120.2
  • HPP1
  • Hyperplastic polyposis protein 1
  • TENB2
  • TMEFF2
  • TPEF
  • TR
  • TR-2
  • Tomoregulin-2
  • cancer/testis antigen family 120, member 2
  • tomoregulin
  • transmembrane protein TENB2
  • transmembrane protein with EGF-like and two follistatin-like domains 2
Description
HPP1 (also called TMEFF2) may be a survival factor for hippocampal and mesencephalic neurons. The shedded form (generated by proteolytic shedding) up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation. HPP1 is down-regulated in tumor cell lines in response to a high level of methylation in the 5' region. The CpG island methylation correlates with HPP1 silencing in tumor cell lines.
Attributes
QA State
Accepted
Type
Genomic
HGNC Name
TMEFF2
Certifications
  • None
QA State for Esophagus
Accepted
Organ-Specific Notes

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.

Supporting Study Data
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:15824739
Barretts Esophagus Methylation Profiles
Study phase on the esophagus: 3

We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.

View Protocol
Decision rule: PMID:15824739
Esophagus-Specific Protocols
  • No organ-level protocols specified for esophagus.
Esophagus-Specific Publications
  • No organ-level publications were listed for esophagus.
Esophagus-Specific Resources
  • No organ-level resources were given for esophagus.